Today is International Psilocybin Mushroom Day, a day of education and action celebrated around the world for the fourth consecutive year. 9/20 hasn’t quite obtained the cultural cache of 4/20, the international day of celebrating cannabis. But it’s not for lack of trying on the part of psilocybin advocates like Nicholas Reville and his all-volunteer 920 Coalition. Under the slogan “Mushrooms are Medicine,” Reville and 920 have brought together over two dozen organizations to host psychedelic-centric events in major cities from Europe to the U.S. and Latin America. Unlike many cannabis events, however, 920 Coalition events are all about research and drug policy. And their pro-shroom claims are bolstered by studies like the one conducted by Johns Hopkins researchers into the use of psilocybin to treat smoking addiction. So in honor of 920, here’s a brief on one of the most landmark recent studies on magic mushrooms.
Johns Hopkins Researchers Update Study on Magic Mushrooms and Smoking Cessation
Dr. Matthew Johnson is a behavioral pharmacologist with Johns Hopkins’ Behavioral Pharmacology Research Unit in Baltimore, Maryland. For twenty years, Johnson has researched the relationships between drugs, the brain, and human behavior. The last decade of his work has focused almost exclusively